Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Regenxbio (RGNX) reported a Q3 loss of $1.17 per share, slightly worse than the Zacks Consensus Estimate of a $1.16 loss. However, this is an improvement from the $1.41 loss per share a year ago.
November 07, 2024 | 12:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Regenxbio reported a Q3 loss of $1.17 per share, slightly missing the consensus estimate of $1.16. Despite the miss, the loss is an improvement from the previous year's $1.41 per share.
The slight miss on earnings per share compared to estimates is balanced by the improvement from the previous year's loss, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100